Literature DB >> 18599565

A comprehensive clinical and biochemical functional study of a novel RPE65 hypomorphic mutation.

Birgit Lorenz1, Eugenia Poliakov, Maria Schambeck, Christoph Friedburg, Markus N Preising, T Michael Redmond.   

Abstract

PURPOSE: Later onset and progression of retinal dystrophy occur with some RPE65 missense mutations. The functional consequences of the novel P25L RPE65 mutation was correlated with its early-childhood phenotype and compared with other pathogenic missense mutations.
METHODS: In addition to typical clinical tests, fundus autofluorescence (FAF), optical coherence tomography (OCT), and two-color threshold perimetry (2CTP) were measured. RPE65 mutations were screened by SSCP and direct sequencing. Isomerase activity of mutant RPE65 was assayed in 293F cells and quantified by HPLC analysis of retinoids.
RESULTS: A very mild phenotype was detected in a now 7-year-old boy homozygous for the P25L mutation in RPE65. Although abnormal dark adaptation was noticed early, best corrected visual acuity was 20/20 at age 5 years and 20/30 at age 7 years. Nystagmus was absent. Cone electroretinogram (ERG) was measurable, rod ERG severely reduced, and FAF very low. 2CTP detected mainly cone-mediated responses in scotopic conditions, and light-adapted cone responses were approximately 1.5 log units below normal. High-resolution spectral domain OCT revealed morphologic changes. Isomerase activity in 293F cells transfected with RPE65/P25L was reduced to 7.7% of wild-type RPE65-transfected cells, whereas RPE65/L22P-transfected cells had 13.5%.
CONCLUSIONS: The mild clinical phenotype observed is consistent with the residual activity of a severely hypomorphic mutant RPE65. Reduction to <10% of wild-type RPE65 activity by homozygous P25L correlates with almost complete rod function loss and cone amplitude reduction. Functional survival of cones is possible in patients with residual RPE65 isomerase activity. This patient should profit most from gene therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18599565      PMCID: PMC5015590          DOI: 10.1167/iovs.07-1671

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  47 in total

1.  Early-onset severe rod-cone dystrophy in young children with RPE65 mutations.

Authors:  B Lorenz; P Gyürüs; M Preising; D Bremser; S Gu; M Andrassi; C Gerth; A Gal
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-08       Impact factor: 4.799

2.  Standard for clinical electroretinography (2004 update).

Authors:  Michael F Marmor; Graham E Holder; Mathias W Seeliger; Shuichi Yamamoto
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

3.  Mutations in RPE65 cause Leber's congenital amaurosis.

Authors:  F Marlhens; C Bareil; J M Griffoin; E Zrenner; P Amalric; C Eliaou; S Y Liu; E Harris; T M Redmond; B Arnaud; M Claustres; C P Hamel
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

4.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

5.  The Rpe65 Leu450Met variation increases retinal resistance against light-induced degeneration by slowing rhodopsin regeneration.

Authors:  A Wenzel; C E Reme; T P Williams; F Hafezi; C Grimm
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

6.  Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA).

Authors:  Ji-Jing Pang; Bo Chang; Norman L Hawes; Ronald E Hurd; Muriel T Davisson; Jie Li; Syed M Noorwez; Ritu Malhotra; J Hugh McDowell; Shalesh Kaushal; William W Hauswirth; Steven Nusinowitz; Debra A Thompson; John R Heckenlively
Journal:  Mol Vis       Date:  2005-02-28       Impact factor: 2.367

7.  Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis.

Authors:  H Morimura; G A Fishman; S A Grover; A B Fulton; E L Berson; T P Dryja
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

Review 8.  State-of-the-art retinal optical coherence tomography.

Authors:  Wolfgang Drexler; James G Fujimoto
Journal:  Prog Retin Eye Res       Date:  2007-08-11       Impact factor: 21.198

9.  Rpe65 as a modifier gene for inherited retinal degeneration.

Authors:  M Samardzija; A Wenzel; M Naash; C E Remé; C Grimm
Journal:  Eur J Neurosci       Date:  2006-02       Impact factor: 3.386

10.  Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients.

Authors:  Francesca Simonelli; Carmela Ziviello; Francesco Testa; Settimio Rossi; Elisa Fazzi; Paolo Emilio Bianchi; Maurizio Fossarello; Sabrina Signorini; Chiara Bertone; Silvana Galantuomo; Francesco Brancati; Enza Maria Valente; Alfredo Ciccodicola; Ernesto Rinaldi; Alberto Auricchio; Sandro Banfi
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

View more
  38 in total

Review 1.  The retinal pigment epithelium in health and disease.

Authors:  J R Sparrow; D Hicks; C P Hamel
Journal:  Curr Mol Med       Date:  2010-12       Impact factor: 2.222

2.  Mutations in RD3 are associated with an extremely rare and severe form of early onset retinal dystrophy.

Authors:  Markus N Preising; Nora Hausotter-Will; Manuel C Solbach; Christoph Friedburg; Franz Rüschendorf; Birgit Lorenz
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-08       Impact factor: 4.799

Review 3.  [Genetic diseases of the retinal pigment epithelium].

Authors:  M N Preising; B Lorenz
Journal:  Ophthalmologe       Date:  2009-04       Impact factor: 1.059

Review 4.  RPE65: role in the visual cycle, human retinal disease, and gene therapy.

Authors:  Xue Cai; Shannon M Conley; Muna I Naash
Journal:  Ophthalmic Genet       Date:  2009-06       Impact factor: 1.803

5.  Aberrant RNA splicing is the major pathogenic effect in a knock-in mouse model of the dominantly inherited c.1430A>G human RPE65 mutation.

Authors:  Yan Li; Rachel Furhang; Amanda Ray; Todd Duncan; Joseph Soucy; Rashid Mahdi; Vijender Chaitankar; Linn Gieser; Eugenia Poliakov; Haohua Qian; Pinghu Liu; Lijin Dong; Igor B Rogozin; T Michael Redmond
Journal:  Hum Mutat       Date:  2019-01-25       Impact factor: 4.878

6.  Structural and functional correlates in color vision deficiency.

Authors:  A Gupta; G Laxmi; M G Nittala; R Raman
Journal:  Eye (Lond)       Date:  2011-04-15       Impact factor: 3.775

7.  Pseudo-fovea formation after gene therapy for RPE65-LCA.

Authors:  Artur V Cideciyan; Geoffrey K Aguirre; Samuel G Jacobson; Omar H Butt; Sharon B Schwartz; Malgorzata Swider; Alejandro J Roman; Sam Sadigh; William W Hauswirth
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-23       Impact factor: 4.799

Review 8.  Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna™) in ophthalmology. English version : January 2019.

Authors: 
Journal:  Ophthalmologe       Date:  2020-01       Impact factor: 1.059

9.  Mouse model of human RPE65 P25L hypomorph resembles wild type under normal light rearing but is fully resistant to acute light damage.

Authors:  Yan Li; Shirley Yu; Todd Duncan; Yichao Li; Pinghu Liu; Erelda Gene; Yoel Cortes-Pena; Haohua Qian; Lijin Dong; T Michael Redmond
Journal:  Hum Mol Genet       Date:  2015-05-13       Impact factor: 6.150

10.  RPE65, visual cycle retinol isomerase, is not inherently 11-cis-specific: support for a carbocation mechanism of retinol isomerization.

Authors:  T Michael Redmond; Eugenia Poliakov; Stephanie Kuo; Preethi Chander; Susan Gentleman
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.